JPRN-UMIN000005714已完成2 期
A Phase II trial of immunotherapy with an anti-PD-1 antibody in advanced / relapsed, Platinum - resistant Ovarian Cancer - A Phase II trial of immunotherapy in advanced / relapsed, Platinum - resistant Ovarian Cancer
Department of Gynecology and Obstetrics, Kyoto University Hospital0 个研究点目标入组 20 人开始时间: 2011年9月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Patients with histories of severe hypersensitive reactions to other antibody drugs. 2) Patients with adverse drug reactions caused by pre-treatment or impacts of complications of surgery or radiation, which are judged to affect the safety assessment of study drug by principle/sub-investigator. 3) Patients with synchronous multiple cancers. 4) Patients with complications of autoimmune disease, histories of chronic and recurrent autoimmune disease or other diseases which require systemic steroid therapy or immune suppressor. 5) Patients with positive test results for HBV, HCV, HIV-1, HIV-2 and HLV-1 antibodies. 6) Patients who are pregnant, nursing or possibly pregnant, or do not agree with contraception until 300 days from the last administration of study drug after informed consent. 7) Patients who received any other study drug or anti-PD-1 antibody within 4 weeks prior to the study drug administration. 8) Patients whom principle/sub-investigator judged ineligible to participate in this study.
研究者
相似试验
已完成
2 期
Phase II trial of anti-PD-1 therapy after anti-PD-L1 therapy in patients with unresectable locally advanced or advanced non-small-cell lung cancernon-small-cell lung cancerJPRN-UMIN000040696ational cancer center hospital75
招募中
2 期
A phase II open-label study with the anti-PD-L1 Atezolizumab monoclonal antibody in combination with Bevacizumab in patients with advanced chemotherapy resistant colorectal cancer and MSI-like molecular signaturebowlecancercolorectal carcinoma10017991NL-OMON49178Vall D'Hebron Institute of Oncology (VHIO)12
进行中（未招募）
1 期
Atezolizumab in combination with Beva in advanced CRC with MSI-like molecular signatureColorectal carcinomaMedDRA version: 20.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002001-19-ESVHIO58
进行中（未招募）
1 期
Atezolizumab in combination with Beva in advanced CRC with MSI-like molecular signatureColorectal carcinomaMedDRA version: 21.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002001-19-ITVALL D'HEBRON INSTITUTE OF ONCOLOGY (VHIO)58
进行中（未招募）
1 期
Atezolizumab in combination with Beva in advanced CRC with MSI-like molecular signatureEUCTR2016-002001-19-BEVHIO58